1.
Aygen B, Demirtürk N, Yıldız O, Çelen MK, Çelik İlhami, Barut Şener, et al. Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience. Turkish Journal of Gastroenterology [Internet]. 2020 Jan. 4 [cited 2026 Jan. 1];31(4):305-17. Available from: https://turkjgastroenterol.org/index.php/tjg/article/view/3574